Freedom Myotonic Dystrophy (DM1) Study

Myotonic Dystrophy Type 1 (DM1) is a rare, inherited neuromuscular disease that affects multiple organ systems, leading to progressive muscle weakness, myotonia (difficulty relaxing muscles), cataracts, cardiac abnormalities, and intellectual disability. It is caused by a genetic mutation in the DMPK gene on chromosome 19, in which a CTG repeat is expanded, leading to toxic RNA that disrupts normal cellular function and protein regulation. The severity and age of onset vary, with symptoms ranging from mild to severe, including a congenital form that affects newborns.  

Diagnosis is confirmed by molecular genetic testing that detects the expanded CTG repeat length in the DMPK gene. Management focuses on treating the symptoms, which can include physical therapy, medications for myotonia, and assistive devices.

About the investigational medication
In Myotonic Dystrophy type 1 (DM1), a genetic mutation creates toxic RNA molecules that trap important proteins (MBNL1). These proteins are needed to make many other proteins correctly, resulting in the many symptoms of DM1 throughout the body.

The investigational product is designed to act like a "molecular sponge" that binds to these toxic RNA molecules, releasing the trapped proteins so proteins can be formed correctly, potentially correcting symptoms of DM1. The investigational product is administered as an IV infusion over 60 minutes, with 4 total doses administered every 4 weeks. Unlike current treatments that manage symptoms, the study product aims to address the root cause of DM1 by blocking the toxic RNA from causing damage. While this approach has shown promise in laboratory and animal studies, this clinical trial is being conducted to determine if it's safe and effective in humans with DM1.